Clinical Trial Update: Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion [Phase 3]

View source ↗

Summary

This Phase 3 trial compares 4-day versus 7-day infusion durations of drotrecogin alfa activated in sepsis and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• Drotrecogin alfa (activated) (drotrecogin alfa (activated))

Snippet

Sponsor: Eli Lilly and Company | Conditions: Sepsis, Hypotension | Phase 3 | Status: COMPLETED